Related Experiment Video
Updated: May 22, 2026
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo
1Centre de Génétique Moléculaire et Cellulaire, CNRS UMR5534, Université Lyon 1, Université de Lyon, 43 Bd 11 Novembre 1918, 69622 Villeurbanne Cedex, France. benjamin.gibert@lyon.unicancer.fr
Background:
The small stress heat shock protein 27 (Hsp27) has recently turned as a promising target for cancer treatment. Hsp27 upregulation is associated with tumour growth and resistance to chemo- and radio-therapeutic treatments, and several ongoing drugs inhibiting Hsp27 expression are under clinical trial. Hsp27 is now well described to counteract apoptosis and its elevated expression is associated with increased aggressiveness of several primary tumours. However, its role in the later stage of tumour progression and, more specifically, in the later and most deadly stage of tumour metastasis is still unclear.
Methods/Results:
In the present study, we showed by qRT-PCR that Hsp27 gene is overexpressed in a large fraction of the metastatic breast cancer area in 53 patients. We further analysed the role of this protein in mice during bone metastasis invasion and establishment by using Hsp27 genetically depleted MDA-MB231/B02 human breast cancer cell line as a model. We demonstrate that Hsp27 silencing led to reduced cell migration and invasion in vitro and that in vivo it correlated with a decreased ability of breast cancer cells to metastasise and grow in the skeleton.
Conclusion:
Altogether, these data characterised Hsp27 as a potent therapeutic target in breast cancer bone metastasis and skeletal tumour growth.
Insights
Small heat shock protein 27 (Hsp27) is overexpressed in metastatic breast cancer. Silencing Hsp27 reduced cancer cell migration and metastasis, indicating Hsp27 is a therapeutic target for bone metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Small heat shock protein 27 (Hsp27) is implicated in tumor growth and treatment resistance.
- Elevated Hsp27 expression correlates with increased tumor aggressiveness.
- The role of Hsp27 in advanced tumor stages, particularly metastasis, remains unclear.
Purpose of the Study:
- To investigate the role of Hsp27 in breast cancer bone metastasis.
- To evaluate Hsp27 as a potential therapeutic target for metastatic breast cancer.
Main Methods:
- Quantitative reverse transcription PCR (qRT-PCR) to assess Hsp27 gene expression in patient samples.
- Utilized a genetically modified human breast cancer cell line (MDA-MB231/B02) with depleted Hsp27.
- In vitro assays for cell migration and invasion, and in vivo studies in a mouse model of bone metastasis.
Main Results:
- Hsp27 gene was found to be overexpressed in metastatic breast cancer tissues from 53 patients.
- Hsp27 silencing significantly reduced breast cancer cell migration and invasion in vitro.
- In vivo, Hsp27 depletion led to decreased metastasis and skeletal tumor growth in a mouse model.
Conclusions:
- Hsp27 plays a critical role in the establishment and growth of breast cancer bone metastasis.
- These findings identify Hsp27 as a promising therapeutic target for treating breast cancer bone metastasis and skeletal tumor progression.
